Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

Treatment Market is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As ...

In fact, the success of biosimilars in Europe has given the United ... UnitedHealthcare announced preferred formulary status for Pfizer’s Retacrit, Amgen’s Mvasi, and Amgen’s Kanjinti.

The NHS saved nearly £99.4 million by using Infliximab, the biosimilar version of Jannssen’s Remicade and £60 million by switching from Amgen/Pfizer’s Enbrel to Etanercept. In addition two ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Introduction The global market for wearable injectors is swiftly growing, propelled by the rising need for self-administration of biologics and ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific ...